
## **STEMI - Antiplatelet Therapy Primary PCI - Summary Clinical Guideline**

Reference No: CG-T/2023/143



\* Ticargrelor is contraindicated in patients taking potent CYP3A4 inhibitors (for example, ketoconazole, clarithromycin, nefazodone, ritonavir, or atazanavir) – use Clopidogrel.

\*\*At discharge, the duration of therapy must be stated

Patients who have a stent thrombosis whilst on Clopidogrel (or who are intolerant of Clopidogrel) should receive Prasugrel (duration and dose at discretion of operator)

Suitable for printing to guide individual patient management but not for storage Expiry date: Dec 2026

Switch from Cangrelor to oral therapy

Cangrelor to Clopidogrel or Prasugrel – give the oral loading dose after the Cangrelor infusion is discontinued

Cangrelor to Ticagrelor – give the oral loading dose as soon as possible, even if still on the infusion

Keywords:

ppci, primary PCI, STEMI, ACS, Clopidogrel, ticagrelor, prasugrel, cangrelor, anti platelet, cardiology, MI, acute coronary syndrome,myocardial infarction

## **Documentation Controls**

Development of Guideline:	Dr J Baron, Dr Kelly, Dr McCance, Dr Azeem, Dr Bhandari, Dr Chitkara, Dr Ahmed, Dr Ahmed, Dr McIntosh, Dr Tukan
Consultation with:	
Approved By:	Cardiology - February 2019 Medical Division - 21/02/2019 Review no change - Cardiology Dec 2023 Medicine Division -
Review Date:	December 2026
Key Contact:	Dr Tariq Azeem, Consultant Cardiologist